Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022. Vice President and CFO Glenn Boehnlein will present virtually at 10:30 a.m. Eastern Time. Interested parties can access a live webcast and replay on Stryker's official website, which will be archived for future viewing. Stryker, a leader in medical technology, aims to enhance healthcare through innovative products and services in diverse areas, including Medical and Surgical, Neurotechnology, Orthopaedics, and Spine.
Stryker (NYSE:SYK) has declared a quarterly dividend of $0.695 per share, set to be paid on April 29, 2022, to shareholders recorded as of March 31, 2022. This marks a 10.3% increase compared to the previous year and remains unchanged from the last quarter. As a leader in medical technology, Stryker is committed to enhancing healthcare through innovative products and services, improving patient and hospital outcomes. For further details, visit www.stryker.com.
Stryker reported strong financial results for Q4 and full year 2021, with net sales up 10.3% year-over-year to $4.7 billion and 19.2% for the year to $17.1 billion. Organic sales rose 9.0% and 12.6% respectively. However, adjusted EPS decreased 3.6% to $2.71. Full-year operating income margin expanded to 25.6%. The company anticipates organic sales growth in 2022 of 6% to 8% despite potential pricing pressures and the ongoing impact of the COVID-19 pandemic.
Stryker (NYSE:SYK) announced a cash tender offer to acquire all outstanding shares of Vocera Communications, Inc. (NYSE:VCRA) for $79.25 per share, initiated on January 25, 2022. This offer follows a merger agreement dated January 6, 2022, and is scheduled to expire on February 22, 2022. The acquisition is contingent on various conditions, including a minimum tender of a majority of Vocera’s shares and regulatory approvals. Vocera's Board of Directors has recommended that its stockholders accept the tender offer. The transaction is expected to close in the first quarter of 2022.
Stryker (NYSE: SYK) has entered into a definitive agreement to acquire Vocera Communications (NYSE: VCRA) for $79.25 per share, totaling approximately $2.97 billion in equity value. The deal enhances Stryker's Medical division by integrating Vocera's innovative digital care coordination platform, which aims to alleviate caregiver burdens and improve patient outcomes. Both companies' boards have unanimously approved the transaction, expected to close in Q1 2022, with a neutral impact on Stryker's 2022 net earnings per share.
Stryker (NYSE:SYK) will host a conference call on January 27, 2022, at 4:30 p.m. ET to discuss its operating results for Q4 2021, with final results released at 4:05 p.m. the same day. Interested parties can register for the call through this link. The call will also be available via a webcast on Stryker's Investor Relations page. A replay will be accessible afterward at provided numbers with a passcode.
Stryker is a global leader in medical technology, focusing on improving healthcare outcomes through innovative products.
Stryker (NYSE:SYK) announced a quarterly dividend increase to $0.695 per share, payable on January 31, 2022, to shareholders of record as of December 31, 2021. This marks a 10.3% increase compared to the previous year and quarter. CEO Kevin Lobo emphasized the company's strong sales growth and solid financial results, aligning with their capital allocation strategy. Stryker is recognized as a leading medical technology firm, focused on improving healthcare through innovative products across Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Moss & Gilmore LLP announced a settlement with the U.S. Department of Justice regarding a False Claims Act lawsuit. Defendants Jeffrey M. Gallups, M.D., and Milton Hall Surgical Associates will pay $3,068,434 to resolve allegations of ordering unnecessary medical tests and surgeries for kickbacks. Entellus Medical, acquired by Stryker Corporation (NYSE:SYK), will also pay $1,200,000 for its involvement. Dr. Gallups previously pleaded guilty to healthcare fraud, with sentencing set for February 11, 2022. Failure to pay may result in a $5,388,863 judgment against them.
Stryker reported third-quarter results for 2021, with net sales of $4.2 billion, representing an 11.3% increase from 2020 and a 16.0% increase from 2019. Although organic net sales rose 4.5% year-over-year, reported operating income margin fell by 260 bps to 25.4%. Reported EPS decreased by 30.1% to $1.14, while adjusted EPS rose 2.8% to $2.20. Key segments showed varied growth, with Orthopaedics increasing by 16.1% but experiencing a decline in organic sales. The company adjusted its 2021 outlook, forecasting organic sales growth of 7% to 8% from 2019.
Stryker (NYSE:SYK) will host an Analyst Meeting on November 18, 2021, at 2:30 p.m. ET, in Mahwah, New Jersey. A webcast of the event will be available on Stryker's website, where it will be archived for later viewing. To join via phone, call (844) 200-6205 (domestic) or (929) 526-1599 (international) with access code 695616. A recorded version will be accessible from 8:30 p.m. ET on November 18 until 11:59 p.m. ET on November 25, 2021. For further inquiries, contact their Investor Relations team.